The pervasive nature of inflammation in the context of ACS and PCI is hard to dispute. Many of the complications and obstacles faced in treating patients with ACS and those undergoing PCI are undoubtedly related to inflammation. Although current therapies employed to treat atherosclerosis and ACS are directed at reducing platelet aggregation, preventing thrombosis, and controlling lipid levels, their ultimate benefit may lie in their ability to modulate inflammation (Fig. 1-9).
Quantification of inflammatory risk may help improve the ability to determine prognosis and to treat many patients with ACS and with coronary atherosclerosis. Much of the evidence for this statement has come from clinical and translational experimental work with currently available medical therapy. Although these various adjuvant therapies are not specifically directed at treating inflammation, their secondary effects on established markers of inflammation have been assessed in numerous studies.
Was this article helpful?